Rivaroxaban plus standard therapy reduces thromboembolic events in HF, CAD patients - Cardiovascular Business

Rivaroxaban plus standard therapy reduces thromboembolic events in HF, CAD patients  Cardiovascular Business

Five milligrams of rivaroxaban per day added to a patient's standard therapy for heart failure (HF) and coronary artery disease (CAD) could reduce that patient's ...



Comments

Popular posts from this blog

Epidemiology and prevention of venous thromboembolism

Deep Vein Thrombosis (DVT): Symptoms, Treatment, & More